Mass spectrometric imaging and quantitative analysis of the <i>in vivo</i> biodistribution of trastuzumab using a rhodium(iii) sarcophagine complex.

ABSTRACT: Mass cytometry with antibodies labelled with stable metal isotopes enables both sensitive imaging and the quantification of protein expression in biological samples. Typically, these specimens are exposed to a panel of labelled antibodies ex vivo, after sample collection. Here, we have developed a rhodium-labelled immunoconjugate of the HER2-targeted therapeutic IgG1 antibody, trastuzumab, and evaluated its in vivo biodistribution using mass cytometry techniques. A Rh³⁺ complex of a macrobicyclic sarcophagine (sar, 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane) chelator was appended with a dibromopyridazinedione (DBPD), to produce a novel disulfide bond labelling molecule, "Rh-sar-DBPD". Rh-sar-DBPD was site-specifically conjugated to trastuzumab via its four

SUBMITTER: Patel N 

PROVIDER: S-EPMC12400293 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature